DOCSLIB.ORG

Molecular Profiling Related to Poor Prognosis in Thyroid Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Profiling Related to Poor Prognosis in Thyroid Carcinoma Oncogene (2008) 27, 1554–1561 & 2008 Nature Publishing Group All rights reserved 0950-9232/08 $30.00 www.nature.com/onc ORIGINAL ARTICLE Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information C Montero-Conde1, JM Martı´ n-Campos2,3, E Lerma4, G Gimenez5, JL Martı´ nez-Guitarte6, N Combalı´ a7, D Montaner8, X Matı´ as-Guiu6, J Dopazo8,9,10, A de Leiva11,12, M Robledo1,9 and D Mauricio11,13 1Hereditary Endocrine Cancer Research Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 2Research Institute, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 3Biochemistry and Molecular Biology Department, Autonomous University of Barcelona (UAB), Barcelona, Spain; 4Pathology Service, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 5Endocrinology Unit, Hospital of Sabadell, Spain; 6Department of Pathology and Molecular Genetics, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain; 7Pathology Service, Hospital of Sabadell, Spain; 8Bioinformatics Department, Centro de Investigacio´n Prı´ncipe Felipe (CIPF), Valencia, Spain; 9ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Spain; 10Functional Genomics Node INB, Spain; 11Department of Endocrinology and Nutrition, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 12ISCIII CIBER-BBN, Spain and 13Department of Endocrinology, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain Undifferentiated and poorly differentiated thyroid tumors provide a potential prognosis predictor as well as targets are responsible for more than half of thyroid cancer for new therapies. patient deaths in spite of their low incidence. Conventional Oncogene (2008) 27, 1554–1561; doi:10.1038/sj.onc.1210792; treatments do not obtain substantial benefits, and the published online 17 September 2007 lack of alternative approaches limits patient survival. Additionally, the absence of prognostic markers for Keywords: anaplastic thyroid cancer; functional profile; well-differentiated tumors complicates patient-specific molecular signature treatments and favors the progression of recurrent forms. In order to recognize the molecular basis involved in tumor dedifferentiation and identify potential markers for thyroid cancer prognosis prediction, we analysed the Introduction expression profile of 44 thyroid primary tumors with different degrees of dedifferentiation and aggressiveness Approximately 122 000 new cases of thyroid carcinoma using cDNA microarrays. Transcriptome comparison of are diagnosed each year worldwide, and more than dedifferentiated and well-differentiated thyroid tumors 90% have a follicular cell origin. Malignant tumors of identified 1031 genes with >2-fold difference in absolute thyroid follicular cells have been classified either as values and false discovery rate of o0.15. According to well-differentiated thyroid carcinoma (WDTC), which known molecular interaction and reaction networks, the is composed of papillary and follicular thyroid carcino- products of these genes were mainly clustered in the ma (PTC and FTC, respectively), or as undifferentiated/ MAPkinase signaling pathway, the TGF-b signaling anaplastic thyroid carcinoma (ATC). The majority of pathway, focal adhesion and cell motility, activation of WDTC are indolent malignancies with a 10-year survival actin polymerization and cell cycle. An exhaustive search of up to 90% (Randolph and Daniels, 2002). In contrast, in several databases allowed us to identify various ATC is one of the most aggressive human malignancies. members of the matrixmetalloproteinase, melanoma Despite its low frequency (o5% of all thyroid carcino- antigen A and collagen gene families within the upregu- mas), ATC is responsible for more than half of thyroid lated gene set. We also identified a prognosis classifier carcinoma deaths, with a mean survivalof 6 months comprising just 30 transcripts with an overall accuracy of after diagnosis (Ain, 1999). However, severalstudies 95%. These findings may clarify the molecular mechan- (Sakamoto et al., 1983; Sobrinho-Simoes et al., 2002) isms involved in thyroid tumor dedifferentiation and confirm the existence of a class of tumors intermediate between WDTC and ATC, namely poorly differentiated thyroid carcinomas (PDTC), which represent entities in Correspondence: Dr M Robledo, Hereditary Endocrine Cancer Group progress from a pre-existing WDTC to ATC, often with Leader, Spanish NationalCancer Centre, MelchorFerna ´ ndez Alma- a similar outcome as ATC. gro 3, E-28029 Madrid, Spain and Dr D Mauricio, Department of Primary treatment of follicular cell-derived tumors, Endocrinology, Arnau de Vilanova Hospital, Av. Alcalde Rovira which has not substantially changed in recent decades, Roure 80, E-25198 Lleida, Spain. 131 E-mails: [email protected] and [email protected] is mainly based on surgical treatment, ablative I Received 9 May 2007; revised 13 July 2007; accepted 9 August 2007; treatment, and suppressive L-thyroxine administration published online 17 September 2007 (Vini and Harmer, 2002). Benefits obtained from Molecular profiling in thyroid cancer C Montero-Conde et al 1555 chemotherapy and radiation therapy remain only Results marginal(Cooper et al., 2006), and metastases, recurrent disease and poorly differentiated/anaplastic Differential gene expression related to tumor tumors still pose major challenges to clinicians. There dedifferentiation is a lack of alternative treatments for tumors with a Genes found differentially expressed in the two pairwise poor response to conventionaltreatment, or those comparisons ATC/PDTC versus FTC and ATC/PDTC with a poor degree of differentiation. We are thus in versus PTC, were assumed to be functionally related to need of new approaches that may lead to improved dedifferentiation and clinical aggressiveness. Genes disease management. Microarray analysis of gene- differentially expressed in only one of the comparisons expression patterns has provided a way to identify were supposed to be related to the specific etiology of molecular events related to specific tumor types and to each WDTC class. specific cancer processes, such as metastasis, prolifera- Taking into account only transcripts common to both tion and angiogenesis (Glinsky, 2006). Numerous pairwise comparisons, 742 clones corresponding to 594 studies also have demonstrated its potential for the genes and 83 ESTs were overexpressed and 678 clones identification of molecular signatures associated with corresponding to 535 genes and 78 ESTs were under- different clinical features (van de Vijver et al., 2002; expressed in the ATC/PDTC tumor set. Huang et al., 2003), that could help identify novel targets for therapy. In the present study, using one of the largest series Functional profiling: pathways and gene families involved of frozen thyroid carcinoma tumors published to date, in malignancy progression in thyroid cancer we have carried out an extensive microarray analysis The FatiScan test for gene set enrichment analysis was followed by an innovative bioinformatics approach, applied to analyse the transcriptional profiles of ATC/ the GEPAS package (Montaner et al., 2006; http:// PDTC versus WDTC. We observed a significant upregu- www.gepas.org), to process and interpret the results lation of the biological process ‘cell cycle progression’ taking into account the clinical data. We have com- (adjusted P-valueo0.05), and a downregulation of pared the gene-expression profiles, obtained using hormone biosynthesis, a thyroid-specific function the CNIO Oncochip, of ATC and PDTC cases (adjusted P-valueo0.05). ‘Cell cycle progression’ versus WDTC samples. We first selected the genes includes mitosis, DNA replication and repair, micro- differentially expressed in ATC/PDTC versus FTC and tubule and actin-filament-based processes, and chromo- ATC/PDTC versus PTC, as representing dedifferentia- some reorganization and biogenesis. tion and clinical aggressiveness features, and analysed The additional analysis of gene biological function their functional implications by identifying molecular revealed gene enrichment in several pathways and pathways involved. We were able to define cellular KEGG terms. Interestingly, the MAPkinase signaling processes important for malignant progression of thyroid pathway, the TGF-b signaling pathway, ‘focal adhesion cancer. Moreover, we found a prognosis signature that and cell motility’, and ‘activation of actin polymeriza- recognizes not only undifferentiated and poorly differ- tion’ presented an overexpression of core genes for entiated tumors, but also recurrent and metastatic pathway activation and an underexpression for inhibi- WDTC. These results may provide new perspectives for tors of the same processes. Table 1 shows the diagnosis, treatment and design of new therapeutic differentially expressed genes (FDR o0.15, >2-fold) strategies for thyroid carcinoma patients with poor within these functionalcategories. We alsofound that prognosis. some of the regulated genes with similar transcription Table 1 Enriched KEGG pathways with over- and underexpressed genes (FDR-adjustedo0.15 and differences in absolute values>2-fold) in ATC/PDTC versus PTC and versus FTC KEGG pathway term Overexpressed genes Underexpressed genes MAPK signaling AKT2, SOS1, FGFR1, MAPK12, ATF4, STMN1, MYC, ELK1, PLA2G6, NF1, CASP2, DUSP14 and CASP9 pathway TGFB2, RAC1, HRAS, CRKL, ARRB2, MINK1, TGFBR2, NRAS, MAP4K4, MKNK1, MAPK8IP1, CDC25B, MAP2K3, PRKCA and MAP3K8 Cell cycle MCM7, MAD2L1, CDK2, PKMYT1, HDAC2, ORC6L, CDKN2C, GSK3B, E2F2, MCM10,
Load more

Recommended publications
  • Ubiquitin-Conjugating Enzyme UBE2J1 Negatively Modulates
    Feng et al. Virology Journal (2018) 15:132 https://doi.org/10.1186/s12985-018-1040-5 RESEARCH Open Access Ubiquitin-conjugating enzyme UBE2J1 negatively modulates interferon pathway and promotes RNA virus infection Tingting Feng1, Lei Deng1, Xiaochuan Lu1, Wen Pan1, Qihan Wu2* and Jianfeng Dai1,2* Abstract Background: Viral infection activates innate immune pathways and interferons (IFNs) play a pivotal role in the outcome of a viral infection. Ubiquitin modifications of host and viral proteins significantly influence the progress of virus infection. Ubiquitin-conjugating enzyme E2s (UBE2) have the capacity to determine ubiquitin chain topology and emerge as key mediators of chain assembly. Methods: In this study, we screened the functions of 34 E2 genes using an RNAi library during Dengue virus (DENV) infection. RNAi and gene overexpression approaches were used to study the gene function in viral infection and interferon signaling. Results: We found that silencing UBE2J1 significantly impaired DENV infection, while overexpression of UBE2J1 enhanced DENV infection. Further studies suggested that type I IFN expression was significantly increased in UBE2J1 silenced cells and decreased in UBE2J1 overexpressed cells. Reporter assay suggested that overexpression of UBE2J1 dramatically suppressed RIG-I directed IFNβ promoter activation. Finally, we have confirmed that UBE2J1 can facilitate the ubiquitination and degradation of transcription factor IFN regulatory factor 3 (IRF3). Conclusion: These results suggest that UBE2 family member UBE2J1 can negatively regulate type I IFN expression, thereby promote RNA virus infection. Keywords: UBE2J1, Dengue virus, Interferons, IRF3, K48 ubiquitination Background antiviral responses [3]. IFN-α/β regulates the synthesis Dengue virus (DENV), transmitted by Aedes aegypti and of antiviral proteins and immunoregulatory factors Aedes albopicuts, causes an emerging tropical disease through the JAK/STAT signaling pathway [4, 5].
    [Show full text]
  • Genome-Wide Analyses on Single Disease Samples for Potential
    Int. J. Biol. Sci. 2018, Vol. 14 833 Ivyspring International Publisher International Journal of Biological Sciences 2018; 14(8): 833-842. doi: 10.7150/ijbs.24816 Research Paper Genome-wide Analyses on Single Disease Samples for Potential Biomarkers and Biological Features of Molecular Subtypes: A Case Study in Gastric Cancer Wei Zeng1,2,3,5, Nini Rao1,2,3,4, Qian Li1,2,3, Guangbin Wang1,2,3, Dingyun Liu1,2,3, Zhengwen Li1,2,3, Yuntao Yang1,2,3 1. Center for Informational Biology, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China. 2. School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, China. 3. Key Laboratory for NeuroInformation of the Ministry of Education, University of Electronic Science and Technology of China, Chengdu 610054, China. 4. Institute of Electronic and Information Engineering of UESTC in Guangdong, Dongguan, 523808, China. 5. Department of Biomedical Engineering, School of Automation and Information Engineering, Sichuan University of Science and Engineering, Zigong, 643000, China Corresponding author: © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2018.01.08; Accepted: 2018.03.06; Published: 2018.05.22 Abstract Purpose: Based on the previous 3 well-defined subtypes of gastric adenocarcinoma (invasive, proliferative and metabolic), we aimed to find potential biomarkers and biological features of each subtype. Methods: The genome-wide co-expression network of each subtype of gastric cancer was firstly constructed.
    [Show full text]
  • Active Rac1 Detection Kit 2012 09/20
    Active Rac1 Detection Kit 1 Kit Orders n 877-616-CELL (2355) (30 immunoprecipitations) [email protected] Support n 877-678-TECH (8324) [email protected] Web n www.cellsignal.com rev. 09/24/20 #8815 For Research Use Only. Not For Use In Diagnostic Procedures. Species Cross-Reactivity: H, M Components Ship As: 11894S Item # Kit Quantity Storage Temp Description: The Active Rac1 Detection Kit provides all GTPgS 11521 1 X 50 µl –80°C reagents necessary for measuring activation of Rac1 GTPase in the cell. GST-PAK1-PBD fusion protein is used to bind GDP 11522 1 X 50 µl –80°C the activated form of GTP-bound Rac1, which can then be Components Ship As: 11894S Item # Kit Quantity Storage Temp immunoprecipitated with glutathione resin. Rac1 activation levels are then determined by western blot using a Rac1 GST-Human PAK1-PBD 8659 1 X 600 µg –20°C Mouse mAb. Rac1 Mouse mAb 8631 1 X 50 µl –20°C Specificity/Sensitivity: Active Rac1 Detection Kit detects Components Ship As: 11860S Item # Kit Quantity Storage Temp endogenous levels of GTP-bound (active) Rac1 as shown in Lysis/Binding/Wash Buffer 11524 1 X 100 mL 4°C Figure 1. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect Glutathione Resin 11523 1 X 3 ml 4°C homologous proteins from other species. SDS Sample Buffer 11525 1 X 1.5 ml 4°C Background: The Ras superfamily of small GTP-binding Spin Cup and Collection Tubes 11526 1 X 30 vial RT proteins (G proteins) comprise a large class of proteins (over 150 members) that can be classified into at least five families based on their sequence and functional similarities: 1 2 3 4 Figure 1.
    [Show full text]
  • Mapping Autosomal Recessive Intellectual Disability: Combined Microarray and Exome
    bioRxiv preprint doi: https://doi.org/10.1101/092346; this version posted March 15, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Mapping Autosomal Recessive Intellectual Disability: Combined Microarray and Exome Sequencing Identifies 26 Novel Candidate Genes in 192 Consanguineous Families Ricardo Harripaul, MSc1,2, Nasim Vasli, PhD1, Anna Mikhailov, BSc1, Muhammad Arshad Rafiq, PhD 1,3, Kirti Mittal, PhD 1, Christian Windpassinger, PhD4, Taimoor I. Sheikh, MPhil1,2, Abdul Noor, PhD5,6, Huda Mahmood, BSc1, Samantha Downey1,7, Maneesha Johnson1,7, Kayla Vleuten1,7, Lauren Bell1,7, Muhammad Ilyas, M.Phil8, Falak Sher Khan, MS9, Valeed Khan, MS9, Mohammad Moradi, MSc10, Muhammad Ayaz11, Farooq Naeem, PhD 11,12, Abolfazl Heidari, PhD1,13, Iltaf Ahmed, PhD14, Shirin Ghadami, PhD15, Zehra Agha, PhD3, Sirous Zeinali, PhD15, Raheel Qamar, PhD3,16, Hossein Mozhdehipanah, MD17, Peter John, PhD14, Asif Mir, PhD8, Muhammad Ansar, PhD9, Leon French, PhD18, Muhammad Ayub, MBBS, MD11,12, John B. Vincent, PhD1,2,19 1Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; 2Institute of Medical Science, University of Toronto, Toronto, ON, Canada; 3Dept. of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan; 4Institute of Human Genetics, Medical University of Graz, Graz, Austria; 5Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; 6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 1 bioRxiv preprint doi: https://doi.org/10.1101/092346; this version posted March 15, 2017.
    [Show full text]
  • Rac1 Accumulates in the Nucleus During the G2 Phase of the Cell
    Published Online: 28 April, 2008 | Supp Info: http://doi.org/10.1083/jcb.200801047 JCB: ARTICLE Downloaded from jcb.rupress.org on May 9, 2018 Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division David Michaelson , 2,5 Wasif Abidi , 2,5 Daniele Guardavaccaro , 4,5 Mo Zhou, 3,5 Ian Ahearn , 3,5 Michele Pagano , 4,5 and Mark R. Philips 1,2,3,5 1 Department of Medicine, 2 Department of Cell Biology, 3 Department of Pharmacology, 4 Department of Pathology, and the 5 New York University Cancer Institute, New York University School of Medicine, New York, NY 10016 ac1 regulates a wide variety of cellular processes. zation of cells stably expressing low levels of GFP-Rac1, The polybasic region of the Rac1 C terminus func- and time-lapse microscopy of asynchronous cells revealed Rtions both as a plasma membrane – targeting motif Rac1 accumulation in the nucleus in late G2 and exclu- and a nuclear localization sequence (NLS). We show that sion in early G1. Although constitutively active Rac1 re- a triproline N-terminal to the polybasic region contributes stricted to the cytoplasm inhibited cell division, activated to the NLS, which is cryptic in the sense that it is strongly Rac1 expressed constitutively in the nucleus increased the inhibited by geranylgeranylation of the adjacent cysteine. mitotic rate. These results show that Rac1 cycles in and out Subcellular fractionation demonstrated endogenous Rac1 of the nucleus during the cell cycle and thereby plays a in the nucleus and Triton X-114 partition revealed that this role in promoting cell division.
    [Show full text]
  • A Drosophila Ortholog of the Human Cylindromatosis Tumor Suppressor
    RESEARCH ARTICLE 2605 Development 134, 2605-2614 (2007) doi:10.1242/dev.02859 A Drosophila ortholog of the human cylindromatosis tumor suppressor gene regulates triglyceride content and antibacterial defense Theodore Tsichritzis1, Peer C. Gaentzsch3, Stylianos Kosmidis2, Anthony E. Brown3, Efthimios M. Skoulakis2, Petros Ligoxygakis3,* and George Mosialos1,4,* The cylindromatosis (CYLD) gene is mutated in human tumors of skin appendages. It encodes a deubiquitylating enzyme (CYLD) that is a negative regulator of the NF-␬B and JNK signaling pathways, in vitro. However, the tissue-specific function and regulation of CYLD in vivo are poorly understood. We established a genetically tractable animal model to initiate a systematic investigation of these issues by characterizing an ortholog of CYLD in Drosophila. Drosophila CYLD is broadly expressed during development and, in adult animals, is localized in the fat body, ovaries, testes, digestive tract and specific areas of the nervous system. We demonstrate that the protein product of Drosophila CYLD (CYLD), like its mammalian counterpart, is a deubiquitylating enzyme. Impairment of CYLD expression is associated with altered fat body morphology in adult flies, increased triglyceride levels and increased survival under starvation conditions. Furthermore, flies with compromised CYLD expression exhibited reduced resistance to bacterial infections. All mutant phenotypes described were reversible upon conditional expression of CYLD transgenes. Our results implicate CYLD in a broad range of functions associated with fat homeostasis and host defence in Drosophila. KEY WORDS: Cylindromatosis, Drosophila, Fat body, Host defense, NF-kappaB INTRODUCTION disease and it is required for the proper development of T Familial cylindromatosis is an autosomal-dominant predisposition lymphocytes in mice (Costello et al., 2005; Reiley et al., 2006).
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Hras Intracellular Trafficking and Signal Transduction Jodi Ho-Jung Mckay Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 HRas intracellular trafficking and signal transduction Jodi Ho-Jung McKay Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cancer Biology Commons, Cell Biology Commons, Genetics and Genomics Commons, and the Medical Cell Biology Commons Recommended Citation McKay, Jodi Ho-Jung, "HRas intracellular trafficking and signal transduction" (2007). Retrospective Theses and Dissertations. 13946. https://lib.dr.iastate.edu/rtd/13946 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. HRas intracellular trafficking and signal transduction by Jodi Ho-Jung McKay A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Genetics Program of Study Committee: Janice E. Buss, Co-major Professor Linda Ambrosio, Co-major Professor Diane Bassham Drena Dobbs Ted Huiatt Iowa State University Ames, Iowa 2007 Copyright © Jodi Ho-Jung McKay, 2007. All rights reserved. UMI Number: 3274881 Copyright 2007 by McKay, Jodi Ho-Jung All rights reserved. UMI Microform 3274881 Copyright 2008 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O.
    [Show full text]
  • Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line
    Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line Mahnaz Nezamivand-Chegini Shiraz University Hamed Kharrati-Koopaee Shiraz University https://orcid.org/0000-0003-2345-6919 seyed taghi Heydari ( [email protected] ) Shiraz University of Medical Sciences https://orcid.org/0000-0001-7711-1137 Hasan Giahi Shiraz University Ali Dehshahri Shiraz University of Medical Sciences Mehdi Dianatpour Shiraz University of Medical Sciences Kamran Bagheri Lankarani Shiraz University of Medical Sciences Research Keywords: Tamoxifen, breast cancer, genetic variants, RNA-seq. Posted Date: August 17th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-783422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Breast cancer is one of the most important causes of mortality in the world, and Tamoxifen therapy is known as a medication strategy for estrogen receptor-positive breast cancer. In current study, two hypotheses of Tamoxifen consumption in breast cancer cell line (MCF7) were investigated. First, the effect of Tamoxifen on genes expression prole at transcriptome level was evaluated between the control and treated samples. Second, due to the fact that Tamoxifen is known as a mutagenic factor, there may be an association between the alterations of genetic variants and Tamoxifen treatment, which can impact on the drug response. Methods In current study, the whole-transcriptome (RNA-seq) dataset of four investigations (19 samples) were derived from European Bioinformatics Institute (EBI). At transcriptome level, the effect of Tamoxifen was investigated on gene expression prole between control and treatment samples.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Myopia Genetics Report
    Special Issue IMI – Myopia Genetics Report Milly S. Tedja,1,2 Annechien E. G. Haarman,1,2 Magda A. Meester-Smoor,1,2 Jaakko Kaprio,3,4 David A. Mackey,5–7 Jeremy A. Guggenheim,8 Christopher J. Hammond,9 Virginie J. M. Verhoeven,1,2,10 and Caroline C. W. Klaver1,2,11; for the CREAM Consortium 1Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands 2Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 3Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland 4Department of Public Health, University of Helsinki, Helsinki, Finland 5Centre for Eye Research Australia, Ophthalmology, Department of Surgery, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia 6Department of Ophthalmology, Menzies Institute of Medical Research, University of Tasmania, Hobart, Tasmania, Australia 7Centre for Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia, Perth, Western Australia, Australia 8School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom 9Section of Academic Ophthalmology, School of Life Course Sciences, King’s College London, London, United Kingdom 10Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands 11Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands Correspondence: Caroline C. W. The knowledge on the genetic background of refractive error and myopia has expanded Klaver, Erasmus Medical Center, dramatically in the past few years. This white paper aims to provide a concise summary of Room Na-2808, P.O. Box 2040, 3000 current genetic findings and defines the direction where development is needed. CA, Rotterdam, the Netherlands; [email protected]. We performed an extensive literature search and conducted informal discussions with key MST and AEGH contributed equally to stakeholders.
    [Show full text]